Businesses
Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Walmart Debuts on Nasdaq, Marking Its First Day of Trading
BENTONVILLE, Arkansas, Dec. 10 -- Walmart issued the following news on Dec. 9, 2025:* * *
Walmart Debuts on Nasdaq, Marking Its First Day of Trading
Company Rings in a New Era with Nasdaq Opening Bell Ceremony
*
Walmart Inc. (Nasdaq: WMT) today announced it has completed the listing transfer of its common stock and bonds to Nasdaq and will begin trading, marking a new chapter in the company's 63-year history of growth, innovation, and long-term value creation for shareholders.
This move follows an evaluation of several factors, including trading execution, brand alignment, and a shared focus ... Show Full Article BENTONVILLE, Arkansas, Dec. 10 -- Walmart issued the following news on Dec. 9, 2025: * * * Walmart Debuts on Nasdaq, Marking Its First Day of Trading Company Rings in a New Era with Nasdaq Opening Bell Ceremony * Walmart Inc. (Nasdaq: WMT) today announced it has completed the listing transfer of its common stock and bonds to Nasdaq and will begin trading, marking a new chapter in the company's 63-year history of growth, innovation, and long-term value creation for shareholders. This move follows an evaluation of several factors, including trading execution, brand alignment, and a shared focuson technology-driven innovation to support Walmart's position as the world's leading omnichannel retailer. As Walmart continues to define and lead the future of global retail, the company is confident that Nasdaq provides the optimal market platform to support its ambitions and continue driving returns for shareholders.
"Our decision to list on Nasdaq reflects Walmart's deep commitment to innovation and growth as a people-led, tech-powered omnichannel retailer," said Doug McMillon, president and CEO of Walmart. "Nasdaq's focus on technology and its support for companies driving digital transformation align perfectly with our strategic vision. This is an exciting next chapter as we continue building a frictionless future for our customers, members, associates, and shareholders."
"Walmart continues to set new standards in convenience, value, and choice, leveraging technology to make retail simpler and more connected," said Adena Friedman, Chair and CEO of Nasdaq. "We are proud to support Walmart's next era of growth as they drive innovation at scale and redefine how communities worldwide engage with commerce."
Walmart's journey in the public markets began on October 1, 1972 when the company listed on the New York Stock Exchange at $16.50 per share. Over the decades, Walmart has demonstrated strong, consistent growth driven by innovation in retail, supply chain, and digital commerce. As the business expanded rapidly in the 1970s through the 1990s, Walmart completed multiple stock splits to broaden its shareholder base and support growing investor demand. These actions, 12 stock splits in total, the most recent in 2024, reflected the company's momentum and its commitment to accessible ownership for associates and long-term investors. Walmart has also increased its annual dividend for more than 40 consecutive years, underscoring its financial strength and dedication to delivering consistent returns.
As Walmart looks ahead, the company is preparing for its next leadership chapter, with John Furner set to become CEO on February 1, 2026. Under his leadership, Walmart will continue to advance its tech-powered vision, modernize its operations, and enhance the shopping experience for customers and members around the world. "We are excited for what lies ahead," McMillon added. "With John Furner as CEO, Walmart will continue to innovate and evolve with a relentless focus on customers, technology, and data-driven decision making."
* * *
About Walmart
Walmart Inc. (Nasdaq: WMT) is a people-led, tech-powered omnichannel retailer helping people save money and live better -- anytime and anywhere -- in stores, online, and through their mobile devices. Each week, approximately 270 million customers and members visit more than 10,750 stores and numerous eCommerce websites in 19 countries. With fiscal year 2025 revenue of $681 billion, Walmart employs approximately 2.1 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy, and employment opportunity. Additional information about Walmart can be found by visiting corporate.walmart.com, on Facebook at facebook.com/walmart, on X (formerly known as Twitter) at twitter.com/walmart, and on LinkedIn at linkedin.com/company/walmart.
* * *
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving as a trusted platform for investors, corporations, and markets around the world. As a leading global exchange operator, Nasdaq is at the forefront of driving innovation and powering the global economy. For more information, visit Nasdaq.com
* * *
Original text here: https://corporate.walmart.com/news/2025/12/09/walmart-debuts-on-nasdaq-marking-Its-first-day-of-trading
[Category: BizConsumer Services]
Unprecedented Results From the Phase 3 MajesTEC-3 Study Support Tecvayli Plus Darzalex Faspro as a Potential Standard of Care as Early as Second Line for Patients With Relapsed/refractory Multiple Myeloma
RARITAN, New Jersey, Dec. 10 -- Johnson and Johnson Innovative Medicine issued the following news release:* * *
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI(R) plus DARZALEX FASPRO(R) as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
TECVAYLI(R) and DARZALEX FASPRO(R) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up
Combination regimen granted Breakthrough Therapy Designation by U.S. FDA
*
Orlando, ... Show Full Article RARITAN, New Jersey, Dec. 10 -- Johnson and Johnson Innovative Medicine issued the following news release: * * * Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI(R) plus DARZALEX FASPRO(R) as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma TECVAYLI(R) and DARZALEX FASPRO(R) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up Combination regimen granted Breakthrough Therapy Designation by U.S. FDA * Orlando,Fla. (December 9, 2025) - Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI(R) (teclistamab-cqyv) plus DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard ratio [HR], 0.17; 95 percent confidence interval [CI], 0.12-0.23; P<0.0001)./1 Ninety-one percent of patients who were progression-free at six months remained progression-free at three years./2
The study evaluated the efficacy and safety of the investigational immunotherapy combination of TECVAYLI(R) plus DARZALEX FASPRO(R) versus DARZALEX FASPRO(R) and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with RRMM who have received 1-3 prior lines of therapy. The data were presented as a late-breaking oral presentation and in the press program at the 2025 American Society of Hematology (ASH) Annual Meeting, with simultaneous publication in The New England Journal of Medicine.
"The combination of TECVAYLI and DARZALEX FASPRO offers remarkable efficacy, a well-characterized safety profile with robust infection management protocols, and an opportunity to improve patient outcomes across academic and community settings. It has the potential to change the standard of care as a steroid-sparing combination regimen suited for outpatient administration on the familiar DARZALEX schedule," said Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Hematology, University Hospital of Salamanca./* "TECVAYLI and DARZALEX FASPRO work synergistically by uniquely targeting both BCMA and CD38 to prime and activate the immune system. The combination has shown to extend progression-free survival and overall survival versus standard of care as early as second line."
Significant improvements compared to standard of care were observed across key secondary endpoints, including treatment response rates, minimal residual disease (MRD)-negativity, overall survival (OS), and time to worsening of symptoms - revealing the comprehensive impact of the combination across varied patient measures./1 TECVAYLI(R) plus DARZALEX FASPRO(R) showed higher rates of complete response (CR) (81.8% vs. 32.1%; odds ratio [OR], 9.56; 95% CI, 6.47-14.14), overall response (89.0% vs. 75.3%; OR, 2.65; 95% CI, 1.68-4.18) and MRD-negativity (58.4% vs. 17.1%; OR, 6.78; 95% CI, 4.53-10.15, P<0.0001; evaluable rate of 89.3% vs. 63.0%) at three-years follow-up./1 OS favored TECVAYLI(R) plus DARZALEX FASPRO(R) (HR, 0.46; 95% CI, 0.32-0.65; P<0.0001) across all prespecified subgroups. At three-years, OS rates were 83.3% and 65.0%, respectively./1 Additionally, patients remained symptom-free significantly longer with TECVAYLI(R) plus DARZALEX FASPRO(R) versus standard of care, underscoring a significant improvement in patient-reported quality of life (QoL) outcomes./1
"With these data, we are entering a new era in treating multiple myeloma with the first bispecific combination to demonstrate superior overall survival as early as second line. Alongside the other transformational therapies in our leading portfolio, we can offer patients optimal outcomes at any stage of disease - bringing us closer to our ultimate ambition to find a cure," said Sen Zhuang, M.D., Vice President, Oncology Clinical Research, Johnson & Johnson Innovative Medicine. "With TECVAYLI plus DARZALEX FASPRO we have the potential to set a new standard of care once again for this disease. We continue to explore how regimens with our bispecifics portfolio can redefine the future for patients."
In the study, TECVAYLI(R) plus DARZALEX FASPRO(R) and standard of care comparators had similar rates of Grade 3/4 (95.1% vs. 96.6%) treatment-emergent adverse events (TEAE)./1 Most Grade 3/4 events were due to cytopenia and infection./1 Infections were observed with TECVAYLI(R) and DARZALEX FASPRO(R) (any grade, 96.5%; Grade 3/4, 54.1%) and DPd/DVd control (any grade 84.1%; Grade 3/4 43.4%). Grade 3 or higher infections with TECVAYLI(R) and DARZALEX FASPRO(R) declined after the first 6 months of treatment with use of established immunoglobulin supplementation and infection prophylaxis protocols, along with switch to monthly dosing./1 Cytokine release syndrome occurred in 60.1% of patients; all cases were Grade 1/2, did not lead to treatment discontinuation and were effectively managed using standard guidelines./1 Immune effector cell-associated neurotoxicity syndrome was rare and occurred in 1.1% of patients./1 Serious adverse events occurred in 70.7% of patients compared to 62.4% of patients treated with the control regimen, while treatment discontinuations due to adverse events were low (4.6% vs. 5.5%)./1 Grade 5 TEAEs were 7.1% and 5.9% with TECVAYLI(R) plus DARZALEX FASPRO(R) and DPd/DVd control, respectively./1
Based on these results, Johnson & Johnson is working with regulatory bodies globally to bring the benefits of this bispecific regimen to eligible patients as quickly as possible. The Company has submitted a supplemental Biologics License Application (sBLA) for the use of TECVAYLI(R) and DARZALEX FASPRO(R) in combination as a treatment for RRMM to the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy Designation (BTD) for the combination regimen; BTD is granted to expedite the development and regulatory review of a medicine that is intended to treat a serious or life-threatening condition and is based on preliminary clinical evidence that demonstrates the drug may have substantial improvement over available therapies on a clinically significant endpoint(s).
The sBLA is being reviewed through the Real-Time Oncology Review (RTOR) program, which enables the agency to initiate their evaluation of the data before the full application is formally submitted. An application has also been submitted to Brazil's health agency, ANVISA (Agencia Nacional de Vigilancia Sanitaria).
About the MajesTEC-3 Study
MajesTEC-3 (NCT05083169) is an ongoing, Phase 3 randomized study evaluating the safety and efficacy of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients with relapsed/refractory multiple myeloma who have received 1-3 prior lines of therapy. The primary endpoint is progression-free survival (PFS) and secondary endpoints include complete response or better (CR), overall response rate, minimal residual disease (MRD)-negativity (10-5 by next-generation sequencing), overall survival (OS), time to worsening of symptoms (MySIm-Q), and safety. The MajesTEC-3 study is a part of the MajesTEC clinical program, which includes exploring the potential of teclistamab as a combination regimen./3
About TECVAYLI(R)
TECVAYLI(R) (teclistamab-cqyv) is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen (BCMA) expressed on the surface of multiple myeloma cells and some healthy B-lineage cells. TECVAYLI(R) received accelerated approvalfrom the U.S. FDA in October 2022 as an off-the-shelf (or ready-to-use) antibody that is administered as a subcutaneous treatment for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody./4
In February 2024, the U.S. FDA approved the supplemental Biologics License Application (sBLA) for TECVAYLI(R) for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a CR or better for a minimum of six months. Since FDA approval, more than 20,800 patients have been treated worldwide with TECVAYLI(R).
The European Commission (EC) granted TECVAYLI(R) conditional marketing authorization in August 2022 as monotherapy for the treatment of adult patients with RRMM who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and have demonstrated disease progression since the last therapy. In August 2023, the EC granted the approval of a Type II variation application for TECVAYLI(R), providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients who have achieved a complete response or better for a minimum of six months.
For more information, visit www.TECVAYLI.com.
About DARZALEX FASPRO(R) and DARZALEX(R)
DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj) received U.S. FDA approval in May 2020 and is approved for 11 indications in multiple myeloma, four of which are for frontline treatment in newly diagnosed patients who are transplant eligible or ineligible./5 It is the only subcutaneous CD38-directed antibody approved to treat patients with multiple myeloma. DARZALEX FASPRO(R) is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE(R) drug delivery technology.
DARZALEX(R) (daratumumab) received U.S. FDA approval in November 2015 and is approved in eight indications, three of which are in the frontline setting, including newly diagnosed patients who are transplant-eligible and ineligible./6 In 2025, DARZALEX FASPRO(R)was approved by the U.S. FDA and EMA as the first and only treatment for patients with high-risk smoldering multiple myeloma.
DARZALEX(R) is the first CD38-directed antibody approved to treat multiple myeloma./5 DARZALEX(R)-based regimens have been used in the treatment of more than 618,000 patients worldwide and more than 68,000 patients in the U.S. alone.
In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab.
For more information, visit www.DARZALEX.com.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow./7 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace normal cells in the bone marrow with tumors./8 Multiple myeloma is the third most common blood cancer worldwide and remains an incurable disease./9 In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die from the disease./10 People living with multiple myeloma have a 5-year survival rate of 59.8 percent./11 While some people diagnosed with multiple myeloma initially have no symptoms, most patients are diagnosed due to symptoms that can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels and kidney problems or infections./12,13
TECVAYLI(R) IMPORTANT SAFETY INFORMATION
INDICATION AND USAGE
TECVAYLI(R) (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME
Cytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI(R). Initiate treatment with TECVAYLI(R) step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI(R) until CRS resolves or permanently discontinue based on severity.
Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and serious and life-threatening reactions, can occur in patients receiving TECVAYLI(R). Monitor patients for signs or symptoms of neurologic toxicity, including ICANS, during treatment. Withhold TECVAYLI(R) until neurologic toxicity resolves or permanently discontinue based on severity.
TECVAYLI(R) is available only through a restricted program called the TECVAYLI(R) and TALVEY(R) Risk Evaluation and Mitigation Strategy (REMS).
WARNINGS AND PRECAUTIONS
Cytokine Release Syndrome - TECVAYLI(R) can cause cytokine release syndrome (CRS), including life-threatening or fatal reactions. In the clinical trial, CRS occurred in 72% of patients who received TECVAYLI(R) at the recommended dose, with Grade 1 CRS occurring in 50% of patients, Grade 2 in 21%, and Grade 3 in 0.6%. Recurrent CRS occurred in 33% of patients. Most patients experienced CRS following step-up dose 1 (42%), step-up dose 2 (35%), or the initial treatment dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI(R). The median time to onset of CRS was 2 (range: 1 to 6) days after the most recent dose with a median duration of 2 (range: 1 to 9) days. Clinical signs and symptoms of CRS included, but were not limited to, fever, hypoxia, chills, hypotension, sinus tachycardia, headache, and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation).
Initiate therapy according to TECVAYLI(R) step-up dosing schedule to reduce risk of CRS. Administer pretreatment medications to reduce risk of CRS and monitor patients following administration of TECVAYLI(R) accordingly. At the first sign of CRS, immediately evaluate patient for hospitalization. Administer supportive care based on severity and consider further management per current practice guidelines. Withhold or permanently discontinue TECVAYLI(R) based on severity.
TECVAYLI(R) is available only through a restricted program under a REMS.
Neurologic Toxicity including ICANS - TECVAYLI(R) can cause serious or life-threatening neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
In the clinical trial, neurologic toxicity occurred in 57% of patients who received TECVAYLI(R) at the recommended dose, with Grade 3 or 4 neurologic toxicity occurring in 2.4% of patients. The most frequent neurologic toxicities were headache (25%), motor dysfunction (16%), sensory neuropathy (15%), and encephalopathy (13%). With longer follow-up, Grade 4 seizure and fatal Guillain-Barre syndrome (one patient each) occurred in patients who received TECVAYLI(R).
In the clinical trial, ICANS was reported in 6% of patients who received TECVAYLI(R) at the recommended dose. Recurrent ICANS occurred in 1.8% of patients. Most patients experienced ICANS following step-up dose 1 (1.2%), step-up dose 2 (0.6%), or the initial treatment dose (1.8%). Less than 3% of patients developed first occurrence of ICANS following subsequent doses of TECVAYLI(R). The median time to onset of ICANS was 4 (range: 2 to 8) days after the most recent dose with a median duration of 3 (range: 1 to 20) days. The most frequent clinical manifestations of ICANS reported were confusional state and dysgraphia. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.
Monitor patients for signs and symptoms of neurologic toxicity during treatment. At the first sign of neurologic toxicity, including ICANS, immediately evaluate patient and provide supportive therapy based on severity. Withhold or permanently discontinue TECVAYLI(R) based on severity per recommendations and consider further management per current practice guidelines.
Due to the potential for neurologic toxicity, patients are at risk of depressed level of consciousness. Advise patients to refrain from driving or operating heavy or potentially dangerous machinery during and for 48 hours after completion of TECVAYLI(R) step-up dosing schedule and in the event of new onset of any neurologic toxicity symptoms until neurologic toxicity resolves.
TECVAYLI(R) is available only through a restricted program under a REMS.
TECVAYLI(R) and TALVEY(R) REMS - TECVAYLI(R) is available only through a restricted program under a REMS called the TECVAYLI(R) and TALVEY(R) REMS because of the risks of CRS and neurologic toxicity, including ICANS.
Hepatotoxicity - TECVAYLI(R) can cause hepatotoxicity, including fatalities. In patients who received TECVAYLI(R) at the recommended dose in the clinical trial, there was one fatal case of hepatic failure. Elevated aspartate aminotransferase (AST) occurred in 34% of patients, with Grade 3 or 4 elevations in 1.2%. Elevated alanine aminotransferase (ALT) occurred in 28% of patients, with Grade 3 or 4 elevations in 1.8%. Elevated total bilirubin occurred in 6% of patients with Grade 3 or 4 elevations in 0.6%. Liver enzyme elevation can occur with or without concurrent CRS.
Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold TECVAYLI(R) or consider permanent discontinuation of TECVAYLI(R) based on severity.
Infections - TECVAYLI(R) can cause severe, life-threatening, or fatal infections. In patients who received TECVAYLI(R) at the recommended dose in the clinical trial, serious infections, including opportunistic infections, occurred in 30% of patients, with Grade 3 or 4 infections in 35%, and fatal infections in 4.2%.
Monitor patients for signs and symptoms of infection prior to and during treatment with TECVAYLI(R) and treat appropriately. Administer prophylactic antimicrobials according to guidelines. Withhold TECVAYLI(R) or consider permanent discontinuation of TECVAYLI(R) based on severity.
Monitor immunoglobulin levels during treatment with TECVAYLI(R) and treat according to guidelines, including infection precautions and antibiotic or antiviral prophylaxis.
Neutropenia - TECVAYLI(R) can cause neutropenia and febrile neutropenia. In patients who received TECVAYLI(R) at the recommended dose in the clinical trial, decreased neutrophils occurred in 84% of patients, with Grade 3 or 4 decreased neutrophils in 56%. Febrile neutropenia occurred in 3% of patients.
Monitor complete blood cell counts at baseline and periodically during treatment and provide supportive care per local institutional guidelines. Monitor patients with neutropenia for signs of infection. Withhold TECVAYLI(R) based on severity.
Hypersensitivity and Other Administration Reactions - TECVAYLI(R) can cause both systemic administration-related and local injection-site reactions. Systemic Reactions - In patients who received TECVAYLI(R) at the recommended dose in the clinical trial, 1.2% of patients experienced systemic-administration reactions, which included Grade 1 recurrent pyrexia and Grade 1 swollen tongue. Local Reactions - In patients who received TECVAYLI(R) at the recommended dose in the clinical trial, injection-site reactions occurred in 35% of patients, with Grade 1 injection-site reactions in 30% and Grade 2 in 4.8%. Withhold TECVAYLI(R) or consider permanent discontinuation of TECVAYLI(R) based on severity.
Embryo-Fetal Toxicity - Based on its mechanism of action, TECVAYLI(R) may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with TECVAYLI(R) and for 5 months after the last dose.
ADVERSE REACTIONS
The most common adverse reactions (20%) were pyrexia, CRS, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common Grade 3 to 4 laboratory abnormalities (20%) were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets.
Please read full Prescribing Information, including Boxed WARNING, for TECVAYLI(R).
DARZALEX(R) INDICATIONS AND IMPORTANT SAFETY INFORMATION
INDICATIONS
DARZALEX(R) (daratumumab) is indicated for the treatment of adult patients with multiple myeloma:
- In combination with bortezomib, melphalan, and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant
- In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy
- In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant
- In combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor
- In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy
- In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy
- As monotherapy in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
DARZALEX(R) is contraindicated in patients with a history of severe hypersensitivity (eg, anaphylactic reactions) to daratumumab or any of the components of the formulation.
WARNINGS AND PRECAUTIONS
Infusion-Related Reactions
DARZALEX(R) can cause severe and/or serious infusion-related reactions including anaphylactic reactions. These reactions can be life threatening, and fatal outcomes have been reported. In clinical trials (monotherapy and combination: N=2066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions. Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions. The median time to onset was 1.5 hours (range: 0 to 73 hours). Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX(R). Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting, and nausea. Less common signs and symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension and blurred vision.
When DARZALEX(R) dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX(R), the incidence of infusion-related reactions was 11% for the first infusion following ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX(R) following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions. In EQUULEUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days, ie, 8 mg/kg on Day 1 and Day 2, respectively. The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions.
Pre-medicate patients with antihistamines, antipyretics, and corticosteroids. Frequently monitor patients during the entire infusion. Interrupt DARZALEX(R) infusion for reactions of any severity and institute medical management as needed. Permanently discontinue DARZALEX(R) therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care. For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion.
To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX(R) infusions. Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications. Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease.
Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with DARZALEX(R) infusion. If ocular symptoms occur, interrupt DARZALEX infusion and seek immediate ophthalmologic evaluation prior to restarting DARZALEX.
Interference With Serological Testing
Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive indirect antiglobulin test (indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient's serum. The determination of a patient's ABO and Rh blood type is not impacted. Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX(R). Type and screen patients prior to starting DARZALEX(R).
Neutropenia and Thrombocytopenia
DARZALEX(R) may increase neutropenia and thrombocytopenia induced by background therapy. Monitor complete blood cell counts periodically during treatment according to manufacturer's prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX(R) until recovery of neutrophils or for recovery of platelets.
Interference With Determination of Complete Response
Daratumumab is a human immunoglobulin G (IgG) kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein. This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein.
Embryo-Fetal Toxicity
Based on the mechanism of action, DARZALEX(R) can cause fetal harm when administered to a pregnant woman. DARZALEX(R) may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX(R) and for 3 months after the last dose.
The combination of DARZALEX(R) with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, pomalidomide, or thalidomide prescribing information on use during pregnancy.
ADVERSE REACTIONS
The most frequently reported adverse reactions (incidence 20%) were: upper respiratory infection, neutropenia, infusion related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia. The most common hematologic laboratory abnormalities (40%) with DARZALEX(R) are: neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia.
Please click here (https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf) to see the full Prescribing Information.
* * *
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com.
* * *
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of TECVAYLI(R) (teclistamab-cqyv) and DARZALEX FASPRO(R) (daratumumab and hyaluronidase-fihj). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
* * *
Footnotes
*/ Maria-Victoria Mateos, M.D., Ph.D., Consultant Physician in Hematology, University Hospital of Salamanca, has provided consulting, advisory, and speaking services to Johnson & Johnson; she has not been paid for any media work.
1/ Maria-Victoria Mateos, et. al., Phase 3 Randomized Study of Teclistamab Plus Daratumumab Versus Investigator's Choice of Daratumumab and Dexamethasone With Either Pomalidomide or Bortezomib (DPd/DVd) in Patients With Relapsed Refractory Multiple Myeloma (RRMM): Results of MajesTEC-3, 2025 American Society of Hematology Annual Meeting. Accessed December 2025.
2/ Mateos, M.V., Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., et al. (2025) Teclistamab plus daratumumab versus standard regimens in relapsed or refractory multiple myeloma: MajesTEC-3 Trial Results. The New England Journal of Medicine, 393(23), https://doi.org/10.1056/NEJMoa2514663.
3/ MajesTEC-3, NCT05083169. A Phase 3 Randomized Study Comparing Teclistamab + Subcutaneous Daratumumab (Tec-Dara) Versus Daratumumab SC + Pomalidomide + Dexamethasone (DPd) or Daratumumab SC + Bortezomib + Dexamethasone (DVd). https://clinicaltrials.gov/study/NCT05083169. Accessed December 2025.
4/ U.S. FDA Approves TECVAYLI(R) (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. https://www.jnj.com/u-s-fda-approves-tecvayli-teclistamab-cqyv-the-first-bispecific-t-cell-engager-antibody-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma. Accessed December 2025.
5/ DARZALEX FASPRO(R) U.S. Prescribing Information.
6/ DARZALEX(R) U.S. Prescribing Information.
7/ Rajkumar SV. Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. 2020;95(5):548-567. http://www.ncbi.nlm.nih.gov/pubmed/32212178.
8/ National Cancer Institute. Plasma cell neoplasms. National Institutes of Health. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq. Accessed October 2025.
9/ City of Hope. Multiple myeloma: Causes, symptoms & treatments. https://www.cancercenter.com/cancer-types/multiple-myeloma. Accessed December 2025.
10/ American Cancer Society. Myeloma cancer statistics. https://cancerstatisticscenter.cancer.org/types/myeloma. Accessed December 2025.
11/ SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/explorer/. Accessed December 2025.
12/ American Cancer Society. What is multiple myeloma? https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html. Accessed December 2025.
13/ American Cancer Society. Multiple myeloma early detection, diagnosis, and staging. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html. Accessed December 2025.
* * *
Original text here: https://www.jnj.com/media-center/press-releases/unprecedented-results-from-the-phase-3-majestec-3-study-support-tecvayli-plus-darzalex-faspro-as-a-potential-standard-of-care-as-early-as-second-line-for-patients-with-relapsed-refractory-multiple-myeloma
[Category: BizPharmaceuticals]
UCLA Health: Researchers Develop a New Computational Tool to Understand How Genetic Interactions Impact Human Traits
LOS ANGELES, California, Dec. 10 (TNSjou) -- The UCLA Health issued the following news release:* * *
Researchers develop a new computational tool to understand how genetic interactions impact human traits
Research team finds effects of individual variants on a trait are modulated by other genes
*
A new study has developed a powerful computational method that can detect how genes interact with one another to influence complex traits in humans at a scale previously impossible. The new method was applied to massive datasets that pair individual genomes and traits to find evidence for such interactions. ... Show Full Article LOS ANGELES, California, Dec. 10 (TNSjou) -- The UCLA Health issued the following news release: * * * Researchers develop a new computational tool to understand how genetic interactions impact human traits Research team finds effects of individual variants on a trait are modulated by other genes * A new study has developed a powerful computational method that can detect how genes interact with one another to influence complex traits in humans at a scale previously impossible. The new method was applied to massive datasets that pair individual genomes and traits to find evidence for such interactions.The findings, published in Nature Genetics (https://www.nature.com/articles/s41588-025-02411-y), show that a person's genetic background can substantially modify how individual genetic variants affect their traits.
Why it matters
Understanding how genes interact to influence complex traits, such as Body Mass Index or total cholesterol levels, in humans is important for basic biology and precision medicine. Such interactions could explain why two individuals that carry the same genetic risk factor can have different health outcomes or why attempts to use genetic information to predict disease risk from genetics can have poorer accuracy than expected. Evidence for such interactions has been limited partly because of the lack of tools that could deal with the complexity and scale of large genomic datasets.
What the study did
This study develops a powerful computational method, FAME, that can detect and quantify the impact of genetic interactions. Previous approaches, typically attempting to find pairs of genetic variants that interact to influence a trait, struggle to detect interactions that have weak effects. FAME, instead, seeks to find genetic variants whose effect on a trait is modulated by all other genetic variants in a person's genome. By aggregating these weak effects, FAME is able to detect interaction signals that would have been missed by previous approaches. However, aggregating the interaction effects arising from hundreds of thousands of variants across the genome is a computationally daunting challenge. FAME uses sophisticated mathematical techniques that reduce the computational requirements while retaining accuracy.
What they found
Applying FAME to the UK Biobank, a massive dataset containing genetic and trait information from nearly 300,000 European ancestry individuals, the research team found 16 instances of interactions on traits that include cholesterol, liver enzymes, and testosterone. While the interaction effects tend to be small, they are often larger than the effect sizes identified by examining the variant by itself (as is common in Genome-Wide Association Studies of complex traits). Additionally, several of these interaction signals were found to replicate in an independent dataset strengthening the robustness of the findings.
What's next
The team plans on extending FAME to inspect rare variants and disease traits, and to localize the interactions in the genome. While the current study used a dataset of almost exclusively white individuals living in the UK, the team also plans on investigating how interactions vary across diverse populations.
From the experts
"This gives us a new window into how genes work together to influence traits," said senior author, Sriram Sankararaman, who is a professor of Computer Science, Computational Medicine, and Human Genetics at UCLA.
"For years, we've known that genes don't act in isolation, but we lacked the computational tools to detect these interactions at scale," said lead author, Boyang Fu, previously a Ph.D. student at UCLA and now a Postdoctoral Fellow at Harvard Medical School. "FAME allows us to test for genetic interactions across hundreds of thousands of people and millions of genetic variants in a matter of hours--something that was previously impossible. It opens a new exciting perspective to look at sequence to function relationships."
* * *
About the study
"A biobank-scale test of marginal epistasis reveals genome-wide signals of polygenic interaction effects." Nature Genetics 2025 DOI: 10.1038/s41588-025-02411-y.
Research Team
Boyang Fu, Harvard University; Ali Pazokitoroudi, Asha Kar, Albert Xue, Aakarsh Anand, Prateek Anand, Zhengtong Liu, Paivi Pajukanta, Noah Zaitlen, and Sriram Sankararaman, UCLA; Zhuozheng Shi, University of Pennsylvania; Richard Border, Carnegie Mellon University.
Funding and Disclosures
The study was supported by grants from the NIH (GM125055, GM153406, HG006399, R01MH130581, U01MH126798, R01MH122688, R01GM142112, R01HL170604, and R01DK132775), the NSF (CAREER-1943497) and the UCLA Dissertation Year Fellowship. The authors declare no competing interests.
* * *
Original text here: https://www.uclahealth.org/news/release/researchers-develop-new-computational-tool-understand-how
[Category: Medical]
Newmark Arranges Sale of 230,691-Square-Foot Office Assemblage in Dallas' Premier Mixed-Use District
NEW YORK, Dec. 10 -- Newmark Group posted the following news release:* * *
Newmark Arranges Sale of 230,691-Square-Foot Office Assemblage in Dallas' Premier Mixed-Use District
Newmark announces the Company has arranged the sale of The Offices at Park Lane, a two-building, 230,691-square-foot office assemblage at 8070 & 8080 Park Lane, located in one of Dallas' most coveted mixed-use destinations. Newmark Capital Markets Vice Chairmen Chris Murphy, Robert Hill and Gary Carr and Director Austin Sheahan represented the seller, Northwood Investors, in the sale to the buyer, DFWLAND.
"Park Lane ... Show Full Article NEW YORK, Dec. 10 -- Newmark Group posted the following news release: * * * Newmark Arranges Sale of 230,691-Square-Foot Office Assemblage in Dallas' Premier Mixed-Use District Newmark announces the Company has arranged the sale of The Offices at Park Lane, a two-building, 230,691-square-foot office assemblage at 8070 & 8080 Park Lane, located in one of Dallas' most coveted mixed-use destinations. Newmark Capital Markets Vice Chairmen Chris Murphy, Robert Hill and Gary Carr and Director Austin Sheahan represented the seller, Northwood Investors, in the sale to the buyer, DFWLAND. "Park Lanecontinues to outperform because it brings together the fundamentals investors value most today: walkability, transit access and a diversified rent roll in one of Dallas' most amenity-rich districts," said Murphy. "The buyer recognized the rare combination of stabilized cash flow and long-term optionality in a location that remains on the short list for corporate users."
The Offices at Park Lane is 66% leased and features a balanced roster of 16 tenants, including corporate headquarters users such as BOKA Powell, Curtainwall Design Consulting and Condon Tobin. Originally constructed in 1972 and 1975, the buildings have undergone significant modern upgrades and offer a robust amenity package, including a state-of-the-art conference center, tenant lounge, gaming area, furnished outdoor spaces and abundant structured parking.
"Acquiring The Offices at Park Lane gives us a strategic foothold in one of Dallas' most dynamic office markets," said Vijay Borra, CEO of DFWLAND. "With its solid fundamentals and significant long-term growth potential, it represents a cornerstone investment for our portfolio."
Situated within The Shops at Park Lane, a 33.5-acre mixed-use district, the property benefits from an unmatched live-work-play environment with over 540,000 square feet of retail and 570+ luxury residential units steps away. Tenants enjoy immediate access to Whole Foods, Nordstrom Rack, Starbucks and numerous dining and entertainment options. The property offers exceptional connectivity via US-75, Greenville Avenue and Northwest Highway, with a short walk to the Park Lane DART Station and minutes from both LBJ Freeway and Downtown Dallas.
According to Newmark Research, U.S. capital markets activity accelerated in 3Q25 amid rising deal flow and renewed investor confidence. Investment sales grew 19% year-over-year, supported by active private and institutional capital and cap rates that have begun to stabilize. Continued improvement in liquidity and underwriting visibility signals strong momentum heading into 2026.
* * *
About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries ("Newmark"), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark's comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform's global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended September 30, 2025, Newmark generated revenues of over $3.1 billion. As of September 30, 2025, Newmark and its business partners together operated from approximately 170 offices with over 8,500 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.
* * *
Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company's business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
* * *
Original text here: https://www.nmrk.com/insights/press-releases/newmark-arranges-sale-of-230-691-square-foot-office-assemblage-in-dallas-premier-mixed-use-district
[Category: BizReal Estate]
Leonardo DRS and Kingdom of Saudi Arabia Ministry of Defense Agree to Expand Collaboration
ARLINGTON, Virginia, Dec. 10 -- Leonardo DRS, a company that says it provides advanced defense technology to U.S. national security customers and allies around the world, issued the following news release on Dec. 8, 2025:* * *
Leonardo DRS and Kingdom of Saudi Arabia Ministry of Defense Agree to Expand Collaboration
Leonardo DRS, Inc. (NASDAQ: DRS) announced today that it has signed a Memorandum of Intent (MOI) with the Kingdom of Saudi Arabia's Ministry of Defense (MOD) to explore opportunities for MOD ground combat vehicles and dismounted forces in support of the country's Vision 2030 defense ... Show Full Article ARLINGTON, Virginia, Dec. 10 -- Leonardo DRS, a company that says it provides advanced defense technology to U.S. national security customers and allies around the world, issued the following news release on Dec. 8, 2025: * * * Leonardo DRS and Kingdom of Saudi Arabia Ministry of Defense Agree to Expand Collaboration Leonardo DRS, Inc. (NASDAQ: DRS) announced today that it has signed a Memorandum of Intent (MOI) with the Kingdom of Saudi Arabia's Ministry of Defense (MOD) to explore opportunities for MOD ground combat vehicles and dismounted forces in support of the country's Vision 2030 defensemodernization roadmap.
The MOI was signed in Washington, D.C. following announcement of the United States of America's Strategic Defense Agreement with Saudi Arabia. Signing for Leonardo DRS was Bill Guyan, the company's Senior Vice President, Business Development and President, International Business. Eng. Khalid Al-Jawini, Director of Projects for Procurement for the Saudi Arabian Ministry of Defense, signed for the MOD under the oversight of H.E. Dr. Khaled bin Hussein Al-Biyari, Assistant Minister of Defense for Executive Affairs.
The MOI identifies prospective opportunities to collaborate in areas where Leonardo DRS is an industry leader in combat-proven, advanced network computing and combat computing capabilities, including:
High-performance battle management systems providing digital command-and-control tools to give crews real-time awareness, communication, and coordination capabilities on the battlefield.
Advanced C6ISR solutions for units at the brigade level and below to support faster decision-making, provide a broader understanding of the battlefield, deliver network protection, and increase the gathering and sharing of critical intelligence capabilities.
Rugged vehicle computing hardware Multi-Function Rugged Displays, and other high-performance, high-performance computing solutions.
Advanced Vehicle Communication Systems for enhanced command and control while ensuring reliable combat vehicle-based communication.
Advanced mobile situational awareness capabilities for special forces and dismounted soldiers that network sensors and communications.
Vehicle integration and engineering services to support in-country integration teams with complex modernization programs across the Saudi MOD vehicle fleet.
"By signing this MOI, Leonardo DRS is reinforcing its commitment to support the Kingdom of Saudi Arabia with its cutting-edge battlespace communications architecture and vehicle integration services that will deliver a more connected, protected, and combat effective land force," Guyan said. "As a trusted provider of advanced defense technology for the U.S. military and allied militaries around the world, we are proud of the opportunity to potentially expand our relationship in supporting the efforts of Saudi Arabia to advance its national defense strategy."
This MOI aligns with Leonardo DRS' broader strategy to grow its presence in the Middle East and expand industrial cooperation in the region. It builds on the company's Memorandum of Agreement with SAMI Advanced Electronics Company for localization of rugged vehicle hardware to support Vision 2030's goals of growing local industrial capability and enhancing the Kingdom's defense readiness.
Leonardo DRS is a trusted provider of advanced battle management systems, network computing and vehicle integration capabilities for the U.S. military and allied forces around the world. The company is a recognized leader in providing proven, high-performance tactical computing, smart displays, AI-enabled processing, and integrated C4/C5/C6ISR solutions that reduce the cognitive burden on commanders and crews operating in complex combat environments. The systems are designed to deliver real time situational awareness and are scalable, platform agnostic, and support open architectures.
Learn more about our, proven, mission-critical AI-capable combat computing and network computing systems at www.LeonardoDRS.com.
* * *
About Leonardo DRS
Leonardo DRS Inc. (Nasdaq: DRS) is at the forefront of developing transformative defense technologies using its proven agility and delivering innovative solutions for U.S. national security customers and allies worldwide. We specialize in rapidly providing high-performance, multi-domain capabilities across next-generation advanced sensing, network computing, force protection, and electric power and propulsion. Our reputation as a trusted provider is built on a continuous focus on practical innovation, delivering quality, and meeting our customers' most demanding mission requirements. For further information on our complete range of capabilities, visit www.LeonardoDRS.com.
* * *
Forward-Looking Statements
This communication contains statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Those statements reflect current expectations, assumptions and estimates of future performance and economic conditions. The company cautions investors that any forward-looking statements which include contract values, contract performance and our development and production of products are subject to risks and uncertainties that may cause actual results and future trends to differ materially from those matters expressed in or implied by such forward-looking statements.
* * *
Original text here: https://www.leonardodrs.com/news/press-releases/leonardo-drs-and-kingdom-of-saudi-arabia-ministry-of-defense-agree-to-expand-collaboration/
[Category: BizNational Defense]
BAE Systems Selected to Modernize USS Forrest Sherman
ARLINGTON, Virginia, Dec. 10 -- BAE Systems issued the following news release:* * *
BAE Systems selected to modernize USS Forrest Sherman
BAE Systems has received a $123 million contract from the U.S. Navy to modernize the Arleigh Burke-class guided-missile destroyer USS Forrest Sherman (DDG 98).
The total value of the competitively awarded contract could reach $139 million if all options are exercised.
BAE Systems' Norfolk shipyard will begin work aboard the 9,200-ton ship in February 2026 under the Navy Depot Modernization Period (DMP) contract. In addition to underwater hull preservation ... Show Full Article ARLINGTON, Virginia, Dec. 10 -- BAE Systems issued the following news release: * * * BAE Systems selected to modernize USS Forrest Sherman BAE Systems has received a $123 million contract from the U.S. Navy to modernize the Arleigh Burke-class guided-missile destroyer USS Forrest Sherman (DDG 98). The total value of the competitively awarded contract could reach $139 million if all options are exercised. BAE Systems' Norfolk shipyard will begin work aboard the 9,200-ton ship in February 2026 under the Navy Depot Modernization Period (DMP) contract. In addition to underwater hull preservationwork, the team will also recondition the ship's engineering spaces, upgrade its command-and-control equipment, and refurbish the crew's living spaces. The DMP work is expected to be completed in early 2027.
"The modernization of USS Forrest Sherman will be a major project for our team, building upon our recent DMP work," said David M. Thomas, Jr., vice president and general manager of BAE Systems Maritime Solutions Norfolk. "More importantly, our work will ensure that the Forrest Sherman is fit to provide a high level of service in the fleet for many years."
The shipyard completed similar work aboard the guided-missile destroyer USS Nitze (DDG 94) in June 2024, and other types of repair work are currently being performed aboard five Navy and commercially operated vessels.
USS Forrest Sherman is the 48th ship of the Arleigh Burke class and was commissioned in January 2006. The ship is named in honor of former Chief of Naval Operations Admiral Forrest P. Sherman. A previous U.S. Navy destroyer, USS Forrest Sherman (DD 931), also bore the admiral's name and was the lead ship in a class of 18 destroyers built in the 1950s.
BAE Systems recently renamed its U.S. maritime business to Maritime Solutions, reflecting the broadened mission of its shipyards and continued investment in serving a wider range of customers. Today, the company is a leading provider of maintenance and modernization services to the U.S. Navy's fleet of combatant ships; refit and hauling services for privately held leisure vessels and workboats; and fabrication services for U.S. submarine and ship builders. The company operates three full-service shipyards in California, Florida, and Virginia, and it employs a highly skilled, experienced workforce and a large team of suppliers and subcontractors.
* * *
Original text here: https://www.baesystems.com/en/article/bae-systems-selected-to-modernize-uss-forrest-sherman
[Category: BizNational Defense]
Athena Summit: Boosting Your Agency
BOSTON, Massachusetts, Dec. 10 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release:* * *
Athena Summit: Boosting Your Agency
*
Embark on a transformative journey at our second Athena Summit in San Francisco unlike any before it. This full-day experience on December 10, 2025, will be hosted at the Silicon Valley Bank Experience Center.
This immersive day will bring together the brightest women leaders, visionaries, and changemakers to reimagine leadership, career journeys, and the future of work.
From the moment you arrive, you'll step into a curated journey ... Show Full Article BOSTON, Massachusetts, Dec. 10 [Category: BizLaw/Legal] -- Goodwin, a law firm, issued the following news release: * * * Athena Summit: Boosting Your Agency * Embark on a transformative journey at our second Athena Summit in San Francisco unlike any before it. This full-day experience on December 10, 2025, will be hosted at the Silicon Valley Bank Experience Center. This immersive day will bring together the brightest women leaders, visionaries, and changemakers to reimagine leadership, career journeys, and the future of work. From the moment you arrive, you'll step into a curated journeydesigned to expand your thinking, grow your network, and help you shape your Portfolio of Impact(tm).
* Athena's Wisdom Stage: Engage with inspiring keynote presentations and panels featuring thought leaders who will challenge your perspectives on leadership, purpose, and the evolving "why" of work.
* Immersive Interactives: Dive into intimate workshops and discussions in smaller breakout spaces like The Speak Easy and The Wise Owl Vault, where you'll re-envision your career trajectory and explore the power of transitions.
* The Weak Ties Challenge: Build meaningful new connections through structured conversations designed to spark collaboration and opportunity.
* Networking and Connection: Share space with executives, board directors, innovators, and fellow Athena members women who are actively shaping the future.
This Athena Summit is more than an event; it's a catalysta full-day immersive experience designed to challenge your thinking and expand your perspective. You'll leave with fresh insights, meaningful connections, and practical frameworks to navigate your leadership journey with impact.
Goodwin's Mary O'Carroll to be speaking on the "AI as a Teammate" panel, and Mitzi Chang will be speaking on "Trends in Governance."
Space is limited, with priority access for Athena members. The deadline to RSVP is November 25th. Reserve your spot today and start planning your trip if you'll be joining us from out of town.
***
Original text here: https://www.goodwinlaw.com/en/news-and-events/events/2025/12/technology-dpc-athena-summit-boosting-your-agency